71 results
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
19 Apr 24
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
5:16pm
as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
21 Mar 24
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
5:14pm
not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
11 Mar 24
Report of Foreign Private Issuer
4:01pm
not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
23 Feb 24
Report of Foreign Private Issuer
4:00pm
by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
12 Jan 24
NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
5:03pm
by regulatory agencies, NLS’ technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS
6-K
EX-99.1
qy7ow i17yklv2ht7
29 Dec 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
4wja6 c9tmekqln
1 Dec 23
Report of Foreign Private Issuer
7:35am
6-K
EX-99.2
s5f 5lkmy
16 Nov 23
Report of Foreign Private Issuer
4:05pm
6-K
EX-99.1
bsqun6se
25 Oct 23
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
4:30pm
6-K
EX-99.1
tj5p e6hki9
13 Sep 23
Report of Foreign Private Issuer
4:03pm
6-K
EX-99.1
1h4ihpn 1gcyggev4
30 Aug 23
Report of Foreign Private Issuer
5:25pm
6-K
EX-99.1
3djym
20 Jul 23
Report of Foreign Private Issuer
4:06pm
6-K
EX-99.3
54hy8k45a9wlyu
3 Jul 23
NLS Pharmaceutics Releases the Results from its Annual General Meeting
1:22pm
6-K
EX-99.1
3hhzjc43fddp39
14 Jun 23
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
8:37am
6-K
EX-99.1
wv5 lv60rxw6hq
8 May 23
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
8:30am
6-K
EX-99.1
w86g6mg nqwd99aa96g1
2 May 23
Report of Foreign Private Issuer
8:30am
6-K
EX-99.1
okcxd7bo65obuwwk4
22 Dec 22
NLS Pharmaceutics CEO Issues Letter to Shareholders
9:40am
6-K
EX-99.1
m09zu2prh4rnsr
20 Dec 22
Report of Foreign Private Issuer
4:00pm
6-K
EX-99.1
ef68s4q3
14 Dec 22
Current Report
4:01pm